Just caught that Oppenheimer upgraded Vertex Pharmaceuticals earlier this year, moving from Perform to Outperform. Analysts are looking at about 14.51% upside potential from where it was trading back in February, with a $532.50 price target on average. Pretty interesting given the range they're looking at - some pretty bullish calls up at $656, but also some conservative ones around $361.

What caught my eye though was the fund positioning. There's about 2,463 institutions holding VRTX positions, and while the number of holders actually dropped by roughly 8% last quarter, the average fund allocation actually grew by almost 10%. The put/call ratio sitting at 0.87 is showing some bullish sentiment too.

Looking at the big money moves: Capital World Investors still has the largest stake at about 10% of the company, though they trimmed a bit. Capital Research Global Investors actually increased their holding and bumped up their allocation by 19%. The Vanguard funds have solid positions but both decreased their allocations last quarter. JPMorgan Chase cut their position pretty aggressively by over 87% on a portfolio basis.

Revenue is projected to dip about 11% though, so the Oppenheimer upgrade seems to be betting on something specific in their pipeline or execution rather than near-term revenue growth. Worth keeping an eye on if you're tracking healthcare stocks.